Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658499 | 1.00 | DPP4 (0.36) | DPP4DPP8HRH3ALDH1A1HSD11B1 | |
| SCHEMBL19652282 | 0.86 | CHRNB4 (0.35) | HRH3ALDH1A1HSD11B1ACKR3CYP2D6 | |
| SCHEMBL19652223 | 0.83 | SSTR4 (0.38) | HRH3ALDH1A1CYP2D6CA1CA2 | |
| SCHEMBL19652222 | 0.83 | SSTR4 (0.38) | HRH3ALDH1A1CYP2D6CA1CA2 | |
| SCHEMBL19658674 | 0.82 | DRD4 (0.38) | DPP4DPP8HRH3ALDH1A1CYP2D6 | |
| SCHEMBL19658468 | 0.82 | DRD4 (0.38) | DPP4DPP8HRH3ALDH1A1CYP2D6 | |
| SCHEMBL24567770 | 0.81 | ALDH1A1 (0.38) | DPP4DPP8HRH3ALDH1A1CYP2D6 | |
| SCHEMBL21564569 | 0.78 | SSTR4 (0.44) | DPP4DPP8CA1CA2CA12 | |
| SCHEMBL12560950 | 0.78 | KDM1A (0.30) | — | |
| SCHEMBL12258709 | 0.76 | HRH3 (0.50) | DPP4DPP8HRH3ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | DPP4 3303/4885DPP8 3500/4885HRH3 131/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | DPP4 3303/4885DPP8 3500/4885HRH3 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.